Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. ... Lorbrena, the Braftovi-Mektovi combination and Padcev.

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below. The ...

Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations. Arvinas on ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Pfizer Inc.

In the Phase II SWOG S2000 trial, investigators with the SWOG Cancer Research Network are comparing Pfizer's BRAF inhibitor Braftovi (encorafenib) and its MEK inhibitor Mektovi (binimetinib) plus ...

For patients with melanoma that has spread to the brain — a group that has traditionally seen poorer outcomes — a trial led by Zeynep Eroglu, M.D., evaluating triple therapy with Pfizer’s Braftovi ...

Pfizer’s Debt figure was $61 Bil at the end of the most recent quarter, while its market capitalization is $133 Bil (as of 6/2/2025). This implies a poor Debt-to-Equity Ratio of 46.2% (vs. 19.9% ...

Pfizer impresses in colorectal cancer – The company's pill Braftovi, combined with two other cancer treatments, doubled survival time for patients with an aggressive form of colorectal cancer ...